Apimeds Pharmaceuticals UsAPUS -2.04%14 Cash Ratio is 0.17 as of Mar. 2026, which is 76% below its 10-year median of 0.71. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 977 Drug Manufacturers companies, Apimeds Pharmaceuticals Us ranks worse than 78.4% on this metric.
Apimeds Pharmaceuticals Us has a Cash Ratio of 0.17. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Apimeds Pharmaceuticals Us's Cash Ratio or its related term are showing as below:
APUS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.71 Max: 15.55
Current: 0.17
During the past 5 years, Apimeds Pharmaceuticals Us's highest Cash Ratio was 15.55. The lowest was 0.02. And the median was 0.71.
APUS's Cash Ratio is ranked worse than 78.4% of 977
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs APUS: 0.17
Apimeds Pharmaceuticals Us (AMEX:APUS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Apimeds Pharmaceuticals Us Cash Ratio Related Terms
Apimeds Pharmaceuticals Us Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apimeds Pharmaceuticals Us's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apimeds Pharmaceuticals Us Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apimeds Pharmaceuticals Us's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Apimeds Pharmaceuticals Us's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apimeds Pharmaceuticals Us (APUS) has a Cash Ratio of 0.17 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Apimeds Pharmaceuticals Us and its competitors. This is 76% below median its historical median of 0.71. Over the past decade, Apimeds Pharmaceuticals Us' Cash Ratio has ranged from 0.02 to 15.55. According to the industry distribution chart, Apimeds Pharmaceuticals Us ranks #766 out of 977 companies in the Drug Manufacturers industry, placing it in the top 78.4%.
Is Apimeds Pharmaceuticals Us' Cash Ratio too high?
Apimeds Pharmaceuticals Us' current Cash Ratio of 0.17 is 76% below median its 10-year median of 0.71. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 15.55. The Drug Manufacturers industry median Cash Ratio is 0.61. Apimeds Pharmaceuticals Us' value of 0.17 is 72.1% below this industry median. Based on the distribution chart, Apimeds Pharmaceuticals Us ranks #766 out of 977 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Cash Ratio compare to KAYS and BIOE?
According to the Drug Manufacturers industry distribution chart, Apimeds Pharmaceuticals Us ranks #766 out of 977 companies for Cash Ratio. This places Apimeds Pharmaceuticals Us in the lower half of its industry. The industry median Cash Ratio is 0.61. Apimeds Pharmaceuticals Us' value of 0.17 is 72.1% below this benchmark. Historically, Apimeds Pharmaceuticals Us' own Cash Ratio has ranged from 0.02 to 15.55 over the past decade. While the company's 10-year median is 0.71 vs. the industry median of 0.61, Apimeds Pharmaceuticals Us has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.61, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apimeds Pharmaceuticals Us's current Cash Ratio of 0.17 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Apimeds Pharmaceuticals Us and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apimeds Pharmaceuticals Us's current Cash Ratio is 0.17, which is 76% below median its own 10-year median of 0.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Cash Ratio of 0.17. The current Cash Ratio is 0.17, which is 76% below median its 10-year median of 0.71 and 72.1% below the Drug Manufacturers industry median of 0.61. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Cash Ratio is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score
Get the complete analysis for APUS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APUS has been successfully added to your 
